AbbVie Targets Psychedelic-Based Depression Drug Market With $1.2 Billion Deal
AbbVie Targets Psychedelic-Based Depression Drug Market With $1.2 Billion Deal Summary AbbVie will acquire an experimental depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion as it pushes into…
